DOI QR코드

DOI QR Code

Seroprevalence of Dengue Virus Antibody in Korea

한국인에서 뎅기바이러스 항체의 혈청 유병률 연구

  • Lee, Ji Hyen (Department of Pediatrics, Ewha Womans University College of Medicine) ;
  • Kim, Han Wool (Department of Pediatrics, Ewha Womans University College of Medicine) ;
  • Kim, Kyung-Hyo (Department of Pediatrics, Ewha Womans University College of Medicine)
  • 이지현 (이화여자대학교 의과대학 소아과학교실) ;
  • 김한울 (이화여자대학교 의과대학 소아과학교실) ;
  • 김경효 (이화여자대학교 의과대학 소아과학교실)
  • Received : 2018.05.28
  • Accepted : 2018.08.23
  • Published : 2018.12.25

Abstract

Purpose: The number of dengue fever cases is rising due to increasing overseas travel. Vaccination makes severe dengue fever in seronegative individuals after vaccination when they exposure to wild-type dengue virus. We investigated the seroepidemiology of the dengue virus for monitoring of Korean dengue virus immunity and establishing the prevention of dengue infection. Methods: The study was based on 446 residual sera collected from 98 infants (2 months to 1 year old), 152 adolescents (13 to 19 years old), 90 adults (20 to 50 years old), and 106 elderly participants (more than 65 years old) for other studies. Antibody levels for dengue virus immunoglobulin G (IgG) in each age group were measured using an enzyme-linked immunosorbent assay (ELISA). For each dengue virus IgG positive or equivocal result, an IgG ELISA was performed for Japanese encephalitis virus. Results: Of the 446 serum samples, only 1 (0.2%) adolescent had a positive result from the dengue IgG antibody test. In the dengue virus IgG antibody test, 14 (3.1%) samples showed equivocal results (10 adolescents and 4 elderly). In the 1 positive case of dengue virus IgG, the Japanese encephalitis IgG test was also positive. In the 14 equivocal cases of dengue virus IgG, there were 6 positive, 3 equivocal, and 5 negative of Japanese encephalitis IgG. Conclusions: The seroprevalence rate of dengue virus was very low in Koreans. This study provides important data for establishing the policy for preventive measures of dengue fever. It will be necessary to continuously monitor for dengue virus immunity.

목적: 뎅기바이러스 감염 환자 발생은 해외 여행이 증가함에 따라 증가하고 있다. 최근 감염 경험이 없는 사람에게 백신을 접종하면 이후 야생 뎅기바이러스 감염 시 중증 뎅기열 증상을 보일 수 있다고 연구된 바 있다. 따라서, 본 연구는 한국의 다양한 연령군에서 뎅기바이러스에 대한 혈청역학을 연구하였다. 방법: 건강한 영아 98명(2개월-1세), 청소년 152명(13-19세), 성인 90명(20-50세) 및 노인 106명(65세 이상)에서 수집한 혈청 총 446명을 대상으로 하였다. 각 연령군의 뎅기바이러스 immunoglobulin G (IgG) 항체 검사를 ELISA을 통해 측정하였다. 또한 뎅기바이러스 IgG 항체 검사에서 양성 또는 equivocal을 보이는 혈청에 한하여 일본뇌염 바이러스의 IgG 항체를 검사하였다. 결과: 총 446명 검체 중, 청소년군에서 1명(0.2%)만 뎅기바이러스 항체 검사에서 양성으로 나왔다. Equivocal은 14명(3.1%)으로, 청소년군 10명과 노인군 4명이 해당하였다. 뎅기바이러스 IgG 양성이 나온 1명에서 일본뇌염 바이러스 또한 IgG 양성으로 나왔다. 뎅기바이러스 IgG equivocal이 나온 14명에서는 일본뇌염 바이러스 IgG 양성이 6명, equivocal이 3명이었고 음성은 5명이었다. 결론: 한국인에서 뎅기바이러스에 대한 항체 보유율은 매우 낮았다. 본 연구는 향후 뎅기열 예방을 위한 보건 정책 수립에 중요한 자료가 될 수 있을 것이며 향후 지속적인 혈청면역 평가도 필요할 것이다.

Keywords

References

  1. Nimmannitya S. Clinical spectrum and management of dengue haemorrhagic fever. Southeast Asian J Trop Med Public Health 1987;18:392-7.
  2. L'Azou M, Moureau A, Sarti E, Nealon J, Zambrano B, Wartel TA, et al. Symptomatic dengue in children in 10 Asian and Latin American countries. N Engl J Med 2016;374:1155-66. https://doi.org/10.1056/NEJMoa1503877
  3. Hales S, de Wet N, Maindonald J, Woodward A. Potential effect of population and climate changes on global distribution of dengue fever: an empirical model. Lancet 2002;360:830-4. https://doi.org/10.1016/S0140-6736(02)09964-6
  4. Lee SH, Nam KW, Jeong JY, Yoo SJ, Koh YS, Lee S, et al. The effects of climate change and globalization on mosquito vectors: evidence from Jeju Island, South Korea on the potential for Asian tiger mosquito (Aedes albopictus) influxes and survival from Vietnam rather than Japan. PLoS One 2013;8:e68512. https://doi.org/10.1371/journal.pone.0068512
  5. World Health Organization (WHO). Dengue and Severe Dengue [Internet]. Geneva: WHO; 2018 [cited 2018 May 11]. Available from: http://www.who.int/mediacentre/factsheets/fs117/en/.
  6. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, et al. Efficacy and long-term safety of a Dengue vaccine in regions of endemic disease. N Engl J Med 2015;373:1195-206. https://doi.org/10.1056/NEJMoa1506223
  7. Flasche S, Jit M, Rodriguez-Barraquer I, Coudeville L, Recker M, Koelle K, et al. The long-term safety, public health impact, and cost-effectiveness of routine vaccination with a recombinant, live-attenuated dengue vaccine (Dengvaxia): a model comparison study. PLoS Med 2016;13:e1002181. https://doi.org/10.1371/journal.pmed.1002181
  8. Koh BK, Ng LC, Kita Y, Tang CS, Ang LW, Wong KY, et al. The 2005 dengue epidemic in Singapore: epidemiology, prevention and control. Ann Acad Med Singapore 2008;37:538-45.
  9. Ooi EE, Hart TJ, Tan HC, Chan SH. Dengue seroepidemiology in Singapore. Lancet 2001;357:685-6. https://doi.org/10.1016/S0140-6736(00)04137-4
  10. Yew YW, Ye T, Ang LW, Ng LC, Yap G, James L, et al. Seroepidemiology of dengue virus infection among adults in Singapore. Ann Acad Med Singapore 2009;38:667-75.
  11. Raj AS, Munshi S, Shah B. A study on clinical presentation of dengue fever in children. IJSR 2016;5:2272-5. https://doi.org/10.21275/v5i4.NOV163048
  12. Ukey P, Bondade S, Paunipagar P, Powar R, Akulwar S. Study of seroprevalence of dengue fever in central India. Indian J Community Med 2010;35:517-9. https://doi.org/10.4103/0970-0218.74366
  13. Jamjoom GA, Azhar EI, Kao MA, Radadi RM. Seroepidemiology of asymptomatic Dengue virus infection in Jeddah, Saudi Arabia. Virology (Auckl) 2016;7:1-7.
  14. Jeong YE, Kim YH, Cho JE, Han MG, Ju YR. Identification of dengue type 1 virus (DENV-1) in Koreans traveling abroad. Osong Public Health Res Perspect 2011;2:34-40. https://doi.org/10.1016/j.phrp.2011.04.002
  15. Korea Centers for Disease Control and Prevention (KCDCP). Guidelines for Viral Mosquito-born Diseases Prevention and Control [Internet]. Cheongju: KCDCP; 2017 [cited 2018 May 11]. Available from: http://cdc.go.kr/CDC/cms/content/mobile/74/75674_view.html.
  16. Kim H, Lee C, Kim M. A case of imported dengue hemorrhagic fever. Korean J Infect Dis 1995;27:403-6.
  17. Park JH, Lee DW. Dengue fever in South Korea, 2006-2010. Emerg Infect Dis 2012;18:1525-7. https://doi.org/10.3201/eid1809.111811
  18. Korea Centers for Disease Control and Prevention (KCDCP). Disease Web Statistics System [Internet]. Cheongju: KCDCP; 2018 [cited 2018 May 11]. Available from: https://is.cdc.go.kr/dstat/jsp/stat/stat0001.jsp.
  19. Korean Tourism Organization. Information on Tourist Statistics [Internet]. Seoul: Korean Tourism Organization; 2017 [cited 2017 May 11]. Available from: http://kto.visitkorea.or.kr/kor/notice/data/statis/profit/board/view.kto?id=379522&isNotice=true&instanceId=294&rnum=0.
  20. Cobelens FG, Groen J, Osterhaus AD, Leentvaar-Kuipers A, Wertheim-van Dillen PM, Kager PA. Incidence and risk factors of probable dengue virus infection among Dutch travellers to Asia. Trop Med Int Health 2002;7:331-8. https://doi.org/10.1046/j.1365-3156.2002.00864.x
  21. Wilder-Smith A, Schwartz E. Dengue in travelers. N Engl J Med 2005;353:924-32. https://doi.org/10.1056/NEJMra041927
  22. Kim DH, Hong YJ, Lee HJ, Choi BY, Kim CH, Park JO, et al. Immunogenicity and protective effectiveness of Japanese Encephalitis vaccine: a prospective multicenter cohort study. Korean J Pediatr Infect Dis 2013;20:131-8. https://doi.org/10.14776/kjpid.2013.20.3.131
  23. Lee EJ, Cha GW, Ju YR, Han MG, Lee WJ, Jeong YE. Prevalence of neutralizing antibodies to Japanese Encephalitis virus among high-risk age groups in South Korea, 2010. PLoS One 2016;11:e0147841. https://doi.org/10.1371/journal.pone.0147841
  24. Thai KT, Nga TT, Van Nam N, Phuong HL, Giao PT, Hung Q, et al. Incidence of primary dengue virus infections in Southern Vietnamese children and reactivity against other flaviviruses. Trop Med Int Health 2007;12:1553-7. https://doi.org/10.1111/j.1365-3156.2007.01964.x
  25. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 1989;40:444-51. https://doi.org/10.4269/ajtmh.1989.40.444
  26. Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med 2018;379:327-40. https://doi.org/10.1056/NEJMoa1800820
  27. Cha GW, Cho JE, Ju YR, Hong YJ, Han MG, Lee WJ, et al. Comparison of four serological tests for detecting antibodies to Japanese encephalitis virus after vaccination in children. Osong Public Health Res Perspect 2014;5:286-91. https://doi.org/10.1016/j.phrp.2014.08.003
  28. Marrero-Santos KM, Beltran M, Carrion-Lebron J, Sanchez-Vegas C, Hamer DH, Barnett ED, et al. Optimization of the cutoff value for a commercial anti-dengue virus IgG immunoassay. Clin Vaccine Immunol 2013;20:358-62. https://doi.org/10.1128/CVI.00429-12